JW Pharmaceutical said Monday that JW0061, a Wnt-targeted hair loss treatment, has been selected as a project for the “first national new drug development project in 2023.”The company also signed a research and development (R&D) agreement with the Korea Drug Development Fund (KDDF).Under the agreeme
Tweet
